Seqens Seqens

X

Polfa Tarchomin's In & Out Licensing Opportunities, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations shared on PharmaCompass.com

  • Webinars & Exhibitions

  • CMO of Parenteral Dosage Forms

  • R&D & Production of Highly Potent Injectables

PharmaCompass
Polfa Tarchomin VB RMU
Polfa Tarchomin
Poland Flag
Country
Country
Poland
Address
Address
A. Fleminga 2 street, 03-176 Warsaw
Telephone
Telephone
+48 225108333
Client Email
Email
Twitter
Twitter
Contact Info
Others

Powder for Oral Su...
600MG; 42.9MG
Poland
Dossier Availability: Q3 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
500MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for solutio...
1000MG
Poland
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for solutio...
2000MG
Poland
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
1000MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
2000MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
500MG; 250MG
Poland
Dossier Availability: Q1 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
1000MG; 500MG
Poland
Dossier Availability: Q1 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
2000MG; 1000MG
Poland
Dossier Availability: Q1 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
100MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
3.5MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Infusio...
50MG
Poland
Dossier Availability: Q2 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Infusio...
70MG
Poland
Dossier Availability: Q2 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Tablet
0.5MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Tablet
2MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Injec...
1MG/ML
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
1000MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
2000MG
Poland
Dossier Availability: Q4 2023
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
1000000IU
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Injecti...
1000000IU
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Injecti...
2000000IU
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Injecti...
3000000IU
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Coated Tablet
5MG
Poland
Dossier Availability: Q3 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Coated Tablet
10MG
Poland
Dossier Availability: Q3 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Infus...
20MG/ML
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Coated Tablet
10MG
Poland
Dossier Availability: Q2 2027
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Coated Tablet
25MG
Poland
Dossier Availability: Q2 2027
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Granulate Powder f...
3000MG
Poland
Dossier Availability: Q2 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Solutio...
40MG/ML
Poland
Dossier Availability: Q2 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Injec...
250MG/5ML
Poland
Dossier Availability: Q1 2027
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Suspension for Cut...
1.372MG/GM
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Coated Tablet
200MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Tablet
0.5MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Tablet
1MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Tablet
2.5MG
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Injec...
2MG/ML
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Injec...
4MG/ML
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Hard Capsule
150MG
Poland
Dossier Availability: Q3 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Hard Capsule
300MG
Poland
Dossier Availability: Q3 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Injec...
1000MG/2ML
Poland
Dossier Availability: Q3 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Injec...
2500MG/5ML
Poland
Dossier Availability: Q3 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Extended Release T...
1000MG
Poland
Dossier Availability: Q1 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Extended Release T...
500MG
Poland
Dossier Availability: Q1 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Extended Release T...
750MG
Poland
Dossier Availability: Q1 2025
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Injec...
50MG/ML
Poland
Dossier Availability: Q3 2026
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Infusio...
50MG
Poland
Dossier Availability: Q3 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Powder for Infusio...
100MG
Poland
Dossier Availability: Q3 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Gel
20MG/GM
Poland
Dossier Available
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Infus...
10MG/ML
Poland
Dossier Availability: Q3 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Solution for Infus...
20MG/ML
Poland
Dossier Availability: Q3 2024
Polfa Tarchomin VB CB

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY